TriangleNCT03206970 · OUTCOME
Progression-free Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 3 years and 6 months
What was measured
Progression-free survival was defined as the time from the starting date of zanubrutinib to the date of first documentation of disease progression or death, whichever occurred first. Participants who did not have disease progression were censored at their last valid tumor assessment. A six-month progression-free survival rate was defined as no disease progression after treated with zanubrutinib for over six months (under control). The 95% confidence interval (CI) lower bound was 33.1 months while the upper bound could not be estimated.
Analysis population: Safety Analysis Set: All participants who received any dose of study drug.
Groups in this outcome
Zanubrutinib
Zanubrutinib (160 mg) administered BID until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow up, or study termination by sponsor, which comes first.
| Group | Source count |
|---|---|
| Zanubrutinib | 86 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Zanubrutinib | 33.0 | Not reported | 19.4 | NA | NA = Not estimable due to insufficient number of participants with events |
Complete source fields
- classes
- categories
- measurements
- comment
- NA = Not estimable due to insufficient number of participants with events
- group Id
- OG000
- lower Limit
- 19.4
- upper Limit
- NA
- value
- 33.0
- denoms
- counts
- group Id
- OG000
- value
- 86
- units
- Participants
- description
- Progression-free survival was defined as the time from the starting date of zanubrutinib to the date of first documentation of disease progression or death, whichever occurred first. Participants who did not have disease progression were censored at their last valid tumor assessment. A six-month progression-free survival rate was defined as no disease progression after treated with zanubrutinib for over six months (under control). The 95% confidence interval (CI) lower bound was 33.1 months while the upper bound could not be estimated.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Zanubrutinib (160 mg) administered BID until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow up, or study termination by sponsor, which comes first.
- id
- OG000
- title
- Zanubrutinib
- param Type
- MEDIAN
- population Description
- Safety Analysis Set: All participants who received any dose of study drug.
- reporting Status
- POSTED
- time Frame
- Up to 3 years and 6 months
- title
- Progression-free Survival
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice